Eli Lilly and Company (LLY)
It Looks Like Eli Lilly Will Become The Next Trillion Dollar Baby
Eli Lilly is poised to become the first $1 trillion pharmaceutical company, driven by explosive growth in its weight-loss drug, Mounjaro. LLY's earnings and sales growth have been exceptional, with quarterly earnings up 495% and sales up 38% year-over-year, outpacing industry peers. The stock boasts a stellar long-term performance record, outperforming the S&P 500 and earning top momentum and performance grades in the analyst's system.
Is Eli Lilly Stock's Run Too Hot? Here Is How It Can Crash
Eli Lilly stock (NYSE: LLY) has surged by 21% this month, driven by strong third-quarter earnings and a favorable obesity drug pricing deal with the U.S. government. However, this recent success doesn't mean the company is invulnerable to challenges.
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Nov 2025)
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%, before taking a breather this year.
Why cutting drug prices is pushing Eli Lilly's stock toward an all-time high
Even by dramatically lowering the prices of some of its medications, the drug giant is still outpacing its rivals and nearing a trillion-dollar valuation.
Lilly Up 18% in a Month: Should You Buy, Sell or Hold the Stock?
Eli Lilly stock jumps 18% in a month as strong Q3 results, upgraded guidance and rising demand for Mounjaro and Zepbound fuel investor optimism.
Eli Lilly expects US FDA approval for oral obesity drug in March 2026
Eli Lilly expects the U.S. Food and Drug Administration to approve its experimental oral obesity drug, orforglipron, by March 2026, its chief executive said on Thursday.
Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk
President Donald Trump struck landmark deals with Eli Lilly and Novo Nordisk to slash the prices of their blockbuster weight loss drugs. Under the agreements, the monthly out-of-pocket cost of popular injections and upcoming pills could range from $50 to $350, depending on the dosage and insurance coverage a patient has.
Lilly's experimental drug shows promise with 20.1% weight loss in mid-stage trial
Eli Lilly said on Thursday its experimental obesity drug helped patients lose as much as 20.1% of their weight in a mid-stage trial.
Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study
Eli Lilly said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging results in a mid-stage study. The highest dose of the weekly injection, called eloralintide, helped patients with obesity or who are overweight lose 20.1% of their body weight on average at 48 weeks.
Novo, Lilly shares rise as Trump obesity drug deal nears
Shares of obesity drugmakers Eli Lilly and Novo Nordisk rose early on Thursday in anticipation of a White House deal that would reduce prices of their blockbuster weight-loss treatments in return for expanded market access.
Here's Why Eli Lilly (LLY) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
